ClinicalTrials.Veeva

Menu

Prospective Validation of the DEVA Algorithm for the Prediction of Severe Endometriosis (ValDEVA)

O

One Clinic

Status

Enrolling

Conditions

Endometriosis

Treatments

Diagnostic Test: MRI
Diagnostic Test: transvaginal ultrasound

Study type

Observational

Funder types

Other

Identifiers

NCT05691322
ValDEVA-01

Details and patient eligibility

About

Endometriosis is a chronic disease affecting 1 in 10 women. Its diagnosis is difficult and the time between the first symptoms and diagnosis is of about 7 years. diagnosis requires specialized imaging performed by referral practitioners for this pathology. According to current recommendations, non-specialized pelvic ultrasound is the recommended first-line examination. However, only reference ultrasound, performed by a doctor specialized in the disease and carried out according to a specific protocol (such as UBESS), is sufficiently reliable for diagnosis. The number of practitioners performing this type of examination is very low in France, which in practice results in a very low reliability of this strategy in real life. Pelvic MRI is also a much more reliable examination, available for review. However its access is limited. In addition, the false positive rate can be as high as 20%, particularly for minor forms of the disease.

The DEVA algorithm has been developed for the identification of women with endometriosis based on a self-administered pelvic pain symptom questionnaire (ENDOPAIN). In a preliminary study, this algorithm seems reliable for identify patients at high risk of this disease and would thus allow to triage patients requiring patients requiring an immediate MRI in order to shorten diagnostic delays. External validation of the algorithm is therefore necessary before clinical use. The main objective od this study is the prospective external validation of the diagnostic reliability of the DEVA algorithm used for the detection of women with endometriosis (visible on MRI or transvaginal ultrasound).

Enrollment

276 estimated patients

Sex

Female

Ages

18 to 45 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Female patients
  • patients aged 18-45
  • Patients addressed for an pelvic IRM or transvaginal echography

Exclusion criteria

  • Minor patients
  • Patients Over 45 years of age
  • Patients without social security
  • Patients that do not know how to read in French
  • Patients with a chronic pathology responsible of pain or handicap
  • Patients with a major pelvic pathology
  • Patients with more than 3 months of amenorrhea
  • Patients diagnosed or suspicious of having an invasive cancer.

Trial contacts and locations

1

Loading...

Central trial contact

Alba Nicolas-Boluda, PhD; Arnaud Fauconnier, Prof

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems